Evidence for a non‐estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo
Authors:
- 1 January 1992
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 20 (1) , 43-50
Abstract
Estramustine is one of the main metabolites of estramustine phosphate (EstracytR), a drug used in the treatment of advanced prostatic cancer. In the present study the hormone independent human prostatic carcinoma cell line DU 145 implanted subcutaneously in nude mice (NMRI) was used to investigate the mode of action of estramustine in vivo. Metaphase arrest was found in mice treated with estramustine intraperitoneally, 200 and 400 μg daily for 2 weeks, 5 days a week. A significant dose dependent decrease in the number of anaphase figures was found. A 7 to 8 fold increase in the number of abnormal metaphases, i.e., highly contracted and unaligned chromosomes, was found. Uptake and retention of 3H‐estramustine was found in tumour tissue. No increase in the mitotic index or the number of abnormal metaphases was found in animals treated with polyestradiol phosphate (EstradurinR). This is the first time evidence has been presented demonstrating the anti‐mitotic effect of estramustine in vivo.Keywords
This publication has 16 references indexed in Scilit:
- Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from purified tubulin with either tau, MAP2, or the tubulin-binding fragment of MAP2Archives of Biochemistry and Biophysics, 1987
- Estramustine Phosphate Compared with Diethylstilbestrol A Randomized, Double-Blind, Crossover Trial for Stage D Prostate CancerAmerican Journal of Clinical Oncology, 1986
- Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3The Prostate, 1984
- Metabolism of estramustine phosphate (Estracyt ®) in patients with prostatic carcinomaEuropean Journal of Drug Metabolism and Pharmacokinetics, 1981
- Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®).Scandinavian Journal of Urology and Nephrology, 1981
- Pilot Study on the Growth Inhibition by Estramustine Phosphate (Estracyt®) of Rat Mammary Tumours Sensitive and Insensitive to OestrogenActa Pharmacologica et Toxicologica, 1979
- Treatment of Advanced Carcinoma of the Prostate with Estramustine PhosphateBritish Journal of Urology, 1977
- Estramustine Phosphate Therapy in Carcinoma of the Prostate1977
- Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)Scandinavian Journal of Urology and Nephrology, 1977
- Extended Therapy of Stage D Carcinoma of the Prostate with Oral Estramustine PhosphateJournal of Urology, 1976